Atherosclerotic Cardiovascular Disease

BOSTON — There is strong evidence for a casual association between lipoprotein(a) concentration and CV outcomes across ethnicities, and Lp(a) “should be measured at least once” in all adults to identify high CV risk, according to a speaker.

The European Society of Cardiology Congress was held Aug. 26 to 29 in Barcelona, Spain, and online, having an in-person component for the first time since 2019.

An expert consensus decision pathway recently issued by the American College of Cardiology addresses lipid-lowering therapies that were developed after the publication of the ACC/American Heart Association cholesterol guidelines in 2018.

RANCHO PALOS VERDES, Calif. — Breast arterial calcification measured during mammography is a readily available surrogate marker of atherosclerotic CVD and may predict subclinical CAD and microvascular disease, according to a speaker.

Early subclinical atherosclerosis among Black vs. Hispanic adults in a socially disadvantaged community.

Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination therapy was noninferior to high-intensity statin monotherapy for major CV outcomes at 3 years, including CV death, data show.

The level of total cholesterol minus HDL and LDL was associated with progression of atherosclerosis, independently of traditional CV risk factors, according to data published in Circulation: Cardiovascular Imaging.

Young Black adults living in a socially disadvantaged community were found to have greater risk for early subclinical atherosclerosis compared with young Hispanic adults in the same community, researchers reported.

PHILADELPHIA — In this Healio video exclusive, Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, discussed her presentation on sex-based disparities in diabetes and their impact on atherosclerotic CVD and HF.